

## Author Index (Vol. 85)

- Alaupovic, P., see Koren, E. (38) 175  
Alcolado, J.C., see Thorn, J.A. (85) 55  
Armstrong, M.L. and Heistad, D.D.  
    Animal models of atherosclerosis (85) 15  
Asada, Y., see Tanimura, N. (85) 161  
Assadollahi, F., see Beaumont, J.-L. (85) 103
- Babaev, V.R., Dergunov, A.D., Chenchik, A.A., Tararak, E.M., Yanushevskaya, E.V., Trakht, I.N., Sorg, C. and Smirnov, V.N.  
    Localization of apolipoprotein E in normal and atherosclerotic human aorta (85) 239  
Barry, L.E. and Tan, M.H.  
    Changes in the composition of plasma lipoproteins in the chronic uremic rat (85) 139  
Beaumont, J.-L. and Assadollahi, F.  
    Retinyl palmitate labeled intestinally derived lipoproteins accumulate in the circulation of WHHL rabbits (85) 103  
Ben-Naim, M., see Harats, D. (85) 47  
Betteridge, D.J., see Jay, R.H. (85) 249  
Blömer, H., see Hauner, H. (85) 203  
Bogaievsky, Y., see Simpson, H.S. (85) 193  
Bond, M.G., see Shankar, R. (85) 37  
Bonithon-Kopp, C., see Raison, J. (85) 185  
Bonnefous, F., see Simpson, H.S. (85) 193  
Boyer, H., De Gennes, J.L., Truffert, J., Chatellier, G., Dairou, F. and Bruckert, E.  
    Lp(a) levels in different types of dyslipidemia in the French population (85) 61  
Broadhurst, P., Kelleher, C., Hughes, L., Imeson, J.D. and Raftery, E.B.  
    Fibrinogen, factor VII clotting activity and coronary artery disease severity (85) 169  
Brown, W.V., see Hunninghake, D.B. (85) 81  
Bruckert, E., see Boyer, H. (85) 61  
Burger, K., see Hauner, H. (85) 203
- Chamberlain, J.C., see Thorn, J.A. (85) 55  
Chan, L., see Thorn, J.A. (85) 55  
Chatellier, G., see Boyer, H. (85) 61  
Chenchik, A.A., see Babaev, V.R. (85) 239  
Chien, S., see Lin, S.-J. (85) 229
- Dabach, Y., see Harats, D. (85) 47  
Dairou, F., see Boyer, H. (85) 61  
Daniel Lamazière, J.M., see Desmoulière, A. (85) 25  
Davenport, A.P., see Weissberg, P.L. (85) 257
- De Gennes, J.L., see Boyer, H. (85) 61  
De Haan, L.H.J., see Zwijsen, R.M.L. (85) 71  
Dergunov, A.D., see Babaev, V.R. (85) 239  
Desmoulière, A., Daniel Lamazière, J.M. and Larrue, J.  
    Phenotypic expression of surface antigens of rabbit aortic smooth muscle cells in culture. Monoclonal antibody, 2P1A2, characteristic of smooth muscle cells present in atherosclerotic plaque, is not correlated with cell proliferation (85) 25  
Dobs, A.S., see Hunninghake, D.B. (85) 81  
Ducimetiere, P., see Raison, J. (85) 185  
Durrington, P.N., see MBewu, A.D. (85) 1
- Egloff, M., see Raison, J. (85) 185
- Filitti, V., see Giral, P. (85) 151  
Franzblau, C., see Kaufmann, J. (85) 113  
Franzen, J., see Koren, E. (38) 175  
Fugate, R.D., see Koren, E. (38) 175
- Galton, D.J., see Thorn, J.A. (85) 55  
Garcia, R.C., see Nakandakare, E. (85) 211  
Giral, P., Filitti, V., Levenson, J., Pithois-Merli, I., Plainfosse, M.-C., Mainardi, C., Gold, A., Simon, A. and PCV-Metra Group,  
    Relation of risk factors for cardiovascular disease to early atherosclerosis detected by ultrasonography in middle-aged normotensive hypercholesterolemic men (85) 151  
Gold, A., see Giral, P. (85) 151  
Goldberg, A.C., see Hunninghake, D.B. (85) 81; (85) 219  
Guy-Grand, B., see Raison, J. (85) 185
- Harats, D., Ben-Naim, M., Dabach, Y., Hollander, G., Havivi, E., Stein, O. and Stein, Y.  
    Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking (85) 47  
Hauner, H., Stangl, K., Schmatz, C., Burger, K., Blömer, H. and Pfeiffer, E.-F.  
    Body fat distribution in men with angiographically confirmed coronary artery disease (85) 203  
Havivi, E., see Harats, D. (85) 47  
Hayashi, T., see Tanimura, N. (85) 161  
Heistad, D.D., see Armstrong, M.L. (85) 15  
Hesketh, T.R., see Weissberg, P.L. (85) 257  
Hollander, G., see Harats, D. (85) 47  
Hughes, L., see Broadhurst, P. (85) 169

- Hunninghake, D.B., Knopp, R.H., Schonfeld, G., Goldberg, A.C., Brown, W.V., Schaefer, E.J., Margolis, S., Dobs, A.S., Mellies, M.J., Insull, Jr., W. and Stein, E.A.  
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study (85) 81
- Hunninghake, D.B., Mellies, M.J., Goldberg, A.C., Kuo, P.T., Kostis, J.B., Schrott, H.G., Insull Jr., W. and Pan, H.Y.  
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing (85) 219
- Hurst, P.G., see Shi, F. (85) 127
- Imeson, J.D., see Broadhurst, P. (85) 169
- Insull, Jr., W., see Hunninghake, D.B. (85) 81; (85) 219
- Jan, K.-m., see Lin, S.-J. (85) 229
- Jay, R.H., Rampling, M.W. and Betteridge, D.J.  
Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment (85) 249
- Jorgensen, R.W., see Kaufmann, J. (85) 113
- Kaufmann, J., Jorgensen, R.W., Martin, B.M. and Franzblau, C.  
Monocyte activation by smooth muscle cell-derived matrices (85) 113
- Kelleher, C., see Broadhurst, P. (85) 169
- Kisanuki, A., see Tanimura, N. (85) 161
- Knopp, R.H., see Hunninghake, D.B. (85) 81
- Koeman, J.H., see Zwijsen, R.M.L. (85) 71
- Koren, E., Franzen, J., Fugate, R.D. and Alaupovic, P.  
Analysis of cholesterol ester accumulation in macrophages by the use of digital imaging fluorescence microscopy (38) 175
- Kostis, J.B., see Hunninghake, D.B. (85) 219
- Kuo, P.T., see Hunninghake, D.B. (85) 219
- Larrue, J., see Desmoulière, A. (85) 25
- Levenson, J., see Giral, P. (85) 151
- Lin, S.-J., Jan, K.-m. and Chien, S.  
Temporal and spatial changes in macromolecular uptake in rat thoracic aorta and relation to [<sup>3</sup>H]thymidine uptake (85) 229
- Lorimer, A.R., see Simpson, H.S. (85) 193
- Macleane, J., see Simpson, H.S. (85) 193
- Mainardi, C., see Giral, P. (85) 151
- Margolis, S., see Hunninghake, D.B. (85) 81
- Martin, B.M., see Kaufmann, J. (85) 113
- MBewu, A.D. and Durrington, P.N.  
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis (85) 1
- McNamara, D.J., see Shi, F. (85) 127
- Mellies, M.J., see Hunninghake, D.B. (85) 81; (85) 219
- Metcalf, J.C., see Weissberg, P.L. (85) 257
- Nakandakare, E., Garcia, R.C., Rocha, J.C., Sperotto, G., Oliveira, H.C.F. and Quintão, E.C.R.  
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins (85) 211
- Oka, K., see Thorn, J.A. (85) 55
- Olivecrona, T., see Simpson, H.S. (85) 193
- Oliveira, H.C.F., see Nakandakare, E. (85) 211
- Oosting, J.S., see Zwijsen, R.M.L. (85) 71
- Packard, C.J., see Simpson, H.S. (85) 193
- Pan, H.Y., see Hunninghake, D.B. (85) 219
- PCV Metra Group, see Giral, P. (85) 151
- Pekelharing, H.L.M., see Zwijsen, R.M.L. (85) 71
- Pfeiffer, E.-F., see Hauner, H. (85) 203
- Pithois-Merli, I., see Giral, P. (85) 151
- Plainfosse, M.-C., see Giral, P. (85) 151
- Pringle, S., see Simpson, H.S. (85) 193
- Quintão, E.C.R., see Nakandakare, E. (85) 211
- Raftery, E.B., see Broadhurst, P. (85) 169
- Raison, J., Bonithon-Kopp, C., Egloff, M., Ducimetiere, P. and Guy-Grand, B.  
Hormonal influences on the relationships between body fatness, body fat distribution, lipids, lipoproteins, glucose and blood pressure in French working women (85) 185
- Rampling, M.W., see Jay, R.H. (85) 249
- Rocha, J.C., see Nakandakare, E. (85) 211
- Schaefer, E.J., see Hunninghake, D.B. (85) 81
- Schmatz, C., see Hauner, H. (85) 203
- Schonfeld, G., see Hunninghake, D.B. (85) 81
- Schrott, H.G., see Hunninghake, D.B. (85) 219
- Shankar, R. and Bond, M.G.  
Correlation of noninvasive arterial compliance with anatomic pathology of atherosclerotic nonhuman primates (85) 37
- Shepherd, J., see Simpson, H.S. (85) 193
- Shi, F., Hurst, P.G. and McNamara, D.J.  
Increased degradation of low density lipoproteins by mononuclear leukocytes associated with coronary artery disease (85) 127
- Simon, A., see Giral, P. (85) 151
- Simpson, H.S., Williamson, C.M., Olivecrona, T., Pringle, S., Maclean, J., Lorimer, A.R., Bonnefous, F., Bogaievsky, Y., Packard, C.J. and Shepherd, J.  
Postprandial lipemia, fenofibrate and coronary artery disease (85) 193
- Smirnov, V.N., see Babaev, V.R. (85) 239
- Sorg, C., see Babaev, V.R. (85) 239
- Sperotto, G., see Nakandakare, E. (85) 211
- Stangl, K., see Hauner, H. (85) 203
- Stein, E.A., see Hunninghake, D.B. (85) 81
- Stein, O., see Harats, D. (85) 47
- Stein, Y., see Harats, D. (85) 47
- Stocks, J., see Thorn, J.A. (85) 55
- Sumiyoshi, A., see Tanimura, N. (85) 161
- Tan, M.H., see Barry, L.E. (85) 139
- Tanimura, N., Asada, Y., Hayashi, T., Kisanuki, A. and Sumiyoshi, A.  
Aortic endothelial cell damage induced by  $\beta$ -VLDL and macrophages in vitro (85) 161

Tararak, E.M., see Babaev, V.R. (85) 239

Thorn, J.A., Chamberlain, J.C., Alcolado, J.C., Oka, K., Chan, L., Stocks, J. and Galton, D.J.

Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis (85) 55

Trakht, I.N., see Babaev, V.R. (85) 239

Truffert, J., see Boyer, H. (85) 61

Weissberg, P.L., Witchell, C., Davenport, A.P., Hesketh, T.R. and Metcalfe, J.C.

The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells (85) 257


Williamson, C.M., see Simpson, H.S. (85) 193

Witchell, C., see Weissberg, P.L. (85) 257

Yanushevskaya, E.V., see Babaev, V.R. (85) 239

Zwijssen, R.M.L., De Haan, L.H.J., Oosting, J.S., Pekelharing, H.L.M. and Koeman, J.H.

Inhibition of intercellular communication in smooth muscle cells of humans and rats by low density lipoprotein, cigarette smoke condensate and TPA (85) 71





## Subject Index (Vol. 85)

---

- Angiography, (85) 203  
Animal models, (85) 15  
Antioxidants, (85) 161  
Aortic endothelial cell injury, (85) 161  
Aortic smooth muscle cells, (85) 113  
Apo B/E receptors, (85) 127  
Apo B localization, (85) 239  
Apo E accumulation, (85) 239  
Apolipoprotein A-I, (85) 139  
Apolipoprotein B, (85) 139  
Apolipoprotein E, (85) 139  
Arterial plaques, (85) 151  
Atherogenesis, (85) 103  
Atherosclerosis, (85) 15; (85) 25; (85) 37; (85) 47; (85) 61; (85) 151; (85) 193; (85) 229; (85) 239  
  
Bezafibrate, (85) 211  
Blood viscosity, (85) 249  
Body fat distribution, (85) 185; (85) 203  
  
Cardiovascular risk factor, (85) 203  
Cardiovascular risk factors, (85) 151  
Cell turnover, (85) 229  
Cholesterol ester, (38) 175  
Cholesterol-feeding, (85) 103  
Cholestyramine, (85) 249  
Chronic uremia, (85) 139  
Chylomicron-Remnants, (85) 103  
Chylomicrons, (85) 193  
Cigarette smoke condensate, (85) 71  
Clinical trial, (85) 81; (85) 219  
Compliance, (85) 37  
Coronary artery disease, (85) 127; (85) 169  
Coronary atherosclerosis, (85) 55  
Coronary heart disease, (85) 203  
Cortisol binding protein, (85) 185  
  
Digital imaging fluorescence microscopy, (38) 175  
DNA, (85) 55  
Dose-response, (85) 81  
  
Efficacy, (85) 219  
Elastin, (85) 113  
Endothelial junction, (85) 229  
Endothelin, (85) 257  
Endothelium, (85) 229  
Evans blue-albumin, (85) 229  
Extracellular matrix, (85) 113  
  
Factor VII activity, (85) 169  
Fat load test, (85) 193  
Fibrinogen, (85) 169; (85) 249  
Free cholesterol/phospholipid molar ratio, (85) 139  
  
Gemfibrozil, (85) 211  
  
HDL, (85) 71  
Hepatic lipase, (85) 55  
High density lipoproteins, (85) 139; (85) 193; (85) 211  
HMG-CoA reductase inhibitors, (85) 81; (85) 219  
Hypercholesterolemia, (85) 151; (85) 249  
Hyperlipidemia, (85) 55; (85) 61  
Hyperlipoproteinemia, (85) 103  
  
Image analysis, (85) 257  
Insulin, (85) 185  
Intercellular communication, (85) 71  
  
LDL, (85) 71  
LDL modification, (85) 47  
LDL peroxidation, (85) 47  
Lipoprotein(a), (85) 61  
Lipoprotein composition, (85) 211  
Lipoprotein lipase, (85) 55; (85) 193  
Lipoproteins, (85) 103  
Lipoprotein ultracentrifugation, (85) 211  
Low density lipoprotein degradation, (85) 127  
Low density lipoproteins, (38) 175; (85) 139; (85) 211  
  
Macrophages, (38) 175; (85) 47  
Metabolic risk factors, (85) 185  
Mitogens, (85) 257  
Monoclonal antibodies, (85) 25  
Monocyte/macrophage, (85) 161  
Monocytes, (85) 113  
Mononuclear leukocyte, (85) 127  
  
NZW rabbits, (85) 103  
  
Overall adiposity, (85) 185  
  
Peripheral arteries, (85) 37  
Permeability, (85) 229  
Phenotypic modulation, (85) 25  
Plasma lipoproteins, (85) 127  
Plasma viscosity, (85) 249  
Platelet-derived growth factor, (85) 257  
Plethysmography, (85) 37

Polymorphism, (85) 55  
Post-heparin lipases, (85) 193  
Pravastatin, (85) 81; (85) 219; (85) 249  
Primary hypercholesterolemia, (85) 219

Red cell aggregation, (85) 249  
Red cell deformability, (85) 249  
Retinyl palmitate, (85) 103  
Reverse cholesterol transport, (85) 239

Safety, (85) 81  
Sex hormone binding globulin, (85) 185  
Simvastatin, (85) 211  
Smoking, (85) 47  
Smooth muscle cells, (85) 25; (85) 47

Thiobarbituric acid reactive substances, (85) 47  
[<sup>3</sup>H]Thymidine, (85) 229  
Transport, (85) 229  
Treatment regimen, (85) 219

Ultrasonography, (85) 151

Validation, (85) 37  
Vascular smooth muscle cells, (85) 257  
Very low density lipoproteins, (85) 139  
Vitamin A, (85) 103  
Vitamin C, (85) 47  
Vitamin E, (85) 47  
 $\beta$ -VLDL, (85) 161

WHHL rabbits, (85) 103

